AG
BPMC

Advisor Group’s Blueprint Medicines BPMC Stock Holding History

Advisor Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$7K Sell
85
-207
-71% -$15.5K ﹤0.01% 4500
2019
Q3 		$21K Buy
292
+3
+1% +$259 ﹤0.01% 3920
2019
Q2 		$28K Sell
289
-90
-24% -$7.43K ﹤0.01% 3745
2019
Q1 		$30K Buy
379
+191
+102% +$14.1K ﹤0.01% 3719
2018
Q4 		$10K Buy
188
+41
+28% +$2.49K ﹤0.01% 4184
2018
Q3 		$11K Buy
147
+133
+950% +$9.24K ﹤0.01% 4228
2018
Q2 		$1K Sell
14
-86
-86% -$6.84K ﹤0.01% 4773
2018
Q1 		$9K Sell
100
-450
-82% -$38.8K ﹤0.01% 4131
2017
Q4 		$41K Buy
550
+50
+10% +$3.52K ﹤0.01% 3215
2017
Q3 		$35K Buy
+500
New +$26.7K ﹤0.01% 3187

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Advisor Group's BPMC Position: Q4 2019 in Review

Advisor Group reduced its Blueprint Medicines (BPMC) stake by 71% in Q4 2019, selling an estimated $15.5K and leaving 85 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #4500.

Advisor Group first reported a position in BPMC in Q3 2017 and has held it in 10 quarters since. The position peaked at $41K in Q4 2017. 228 funds tracked by Wall St. Rank hold BPMC as of Q4 2019.

  • Advisor Group held 85 shares of Blueprint Medicines worth $7K as of Q4 2019.
  • Advisor Group sold 207 Blueprint Medicines shares in Q4 2019, an estimated $15.5K.
  • Blueprint Medicines made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4500 holding.
  • Advisor Group first reported a position in Blueprint Medicines in Q3 2017 and has held it in 10 quarters since.
  • Advisor Group's Blueprint Medicines position peaked at $41K in Q4 2017.
  • 228 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.